Pharmacokinetics of tirzepatide demonstrated dose proportionality over the wide dose range, with C max of 180 nM in individuals treated with one dose of 8 mg and a C max of 260 nM with 15 mg/week dose in the clinical study, exceeding the EC50 values for GIPR and GLP-1R activations by approximately 10,000-fold and 250-fold, respectively (63)
Clinical trials show that patients typically experience weight loss of about 5% to 10% of their initial body weight over several months, which translates to approximately 4 to 8 pounds per month for many individuals
What can I do to protect my bones whilst taking GLP-1 treatment
Clinics that can address post-GLP-1 treatment challenges will stand out in a crowded marketplace ahead of the competition
Volker Musahl, an internationally recognized ACL surgeon and researcher
Two drugmakers are now offering a new generation of these GLP-1 drugs, whose effects on weight loss have been spectacular